AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy
- 20 June 2020
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 87, 13-19
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 73 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- The impact of acetylation and deacetylation on the p53 pathwayProtein & Cell, 2011
- Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of TumorigenesisGenes & Cancer, 2011
- p53 post-translational modification: deregulated in tumorigenesisTrends in Molecular Medicine, 2010
- The Cyclin-Dependent Kinase Inhibitor p21 Is a Crucial Target for Histone Deacetylase 1 as a Regulator of Cellular ProliferationMolecular and Cellular Biology, 2010
- Histone Deacetylase Inhibitors in Cancer TherapyJournal of Clinical Oncology, 2009
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- The role of histone deacetylases (HDACs) in human cancerMolecular Oncology, 2007
- Twenty years of p53 research: structural and functional aspects of the p53 proteinOncogene, 1999